Sivik Global Healthcare LLC Takes $3.73 Million Position in Repligen Corporation $RGEN

Key Points

• Sivik Global Healthcare LLC has acquired a new stake in Repligen Corporation, purchasing 30,000 shares valued at approximately $3.73 million, making it the firm's 27th largest position.
• Wall Street analysts express optimism for Repligen, with several increasing their price targets, now averaging around $169.62, and assigning a consensus rating of "Moderate Buy."
• Despite a recent earnings miss, Repligen reported a revenue increase of 14.8% year-over-year, with projected earnings guidance for FY 2025 between $1.650 and $1.720 EPS.

Sivik Global Healthcare LLC bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 30,000 shares of the biotechnology company's stock, valued at approximately $3,731,000. Repligen makes up about 1.0% of Sivik Global Healthcare LLC's holdings, making the stock its 27th largest position. Sivik Global Healthcare LLC owned about 0.05% of Repligen as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Aberdeen Group plc purchased a new position in shares of Repligen during the 2nd quarter valued at approximately $5,744,000. Trevian Wealth Management LLC purchased a new position in shares of Repligen during the 2nd quarter valued at approximately $679,000. Callan Family Office LLC lifted its position in shares of Repligen by 44.6% during the 2nd quarter. Callan Family Office LLC now owns 4,210 shares of the biotechnology company's stock valued at $524,000 after buying an additional 1,299 shares in the last quarter. Blair William & Co. IL lifted its position in shares of Repligen by 32.7% during the 2nd quarter. Blair William & Co. IL now owns 2,746 shares of the biotechnology company's stock valued at $342,000 after buying an additional 676 shares in the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in shares of Repligen by 0.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 14,700 shares of the biotechnology company's stock valued at $1,828,000 after buying an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Barclays increased their price objective on Repligen from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Hsbc Global Res raised Repligen to a "strong-buy" rating in a research note on Wednesday, October 1st. Jefferies Financial Group reduced their price objective on Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a research note on Friday, September 12th. Finally, Evercore ISI increased their price objective on Repligen from $155.00 to $175.00 and gave the company an "outperform" rating in a research note on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $169.62.

Insider Activity

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, with a total value of $201,834.00. Following the transaction, the director owned 1,800 shares of the company's stock, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Trading Down 2.4%

Shares of RGEN opened at $145.24 on Friday. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The firm has a 50-day moving average price of $125.12 and a 200 day moving average price of $125.62. The firm has a market capitalization of $8.17 billion, a P/E ratio of -580.94, a P/E/G ratio of 2.68 and a beta of 1.08.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. During the same period in the prior year, the company posted $0.40 EPS. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.